The outcome and predictive factors of sunitinib therapy in advanced gastrointestinal stromal tumors (GIST) after imatinib failure - one institution study

<p>Abstract</p> <p>Background</p> <p>Gastrointestinal stromal tumors (GIST) mutational status is recognized factor related to the results of tyrosine kinase inhibitors therapy such as imatinib (IM) or sunitinib (SU). Arterial hypertension (AH) is common adverse event re...

Full description

Bibliographic Details
Main Authors: Rutkowski Piotr, Bylina Elżbieta, Klimczak Anna, Świtaj Tomasz, Falkowski Sławomir, Kroc Jacek, Ługowska Iwona, Brzeskwiniewicz Magdalena, Melerowicz Wojciech, Osuch Czesław, Mierzejewska Ewa, Wasielewski Kacper, Woźniak Agnieszka, Grzesiakowska Urszula, Nowecki Zbigniew I, Siedlecki Janusz A, Limon Janusz
Format: Article
Language:English
Published: BMC 2012-03-01
Series:BMC Cancer
Subjects:
Online Access:http://www.biomedcentral.com/1471-2407/12/107